IPO registrations (S-1, F-1) · Registrants

LeonaBio, Inc.

SEC CIK
1620463 · filings on EDGAR ↗
Former names
Athira Pharma, Inc. (2019–2026); M3 Biotechnology, Inc. (2014–2019)
Registration
Form S-1, first filed 2020-08-26, last 2026-03-31; 2 initial registrations, 5 amendments
Outcome
Final prospectus filed 2020-09-18; declared effective 2020-09-17
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Business address
18706 NORTH CREEK PARKWAY, SUITE 104, Bothell, WA 98011
EIN
45-3368487
Ticker
LONA (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
LeonaBio, Inc. on the corporate pages

Offering terms

Proposed price range
$15.00–$17.00 per share (S-1/A filed 2020-09-17)
Final price
$17.00 per share, within the range (424B4 filed 2020-09-18, an initial public offering)
Shares sold
12,000,000
Gross proceeds
$204,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol ATHA
Lead underwriters
Goldman Sachs; Jefferies
Syndicate
Stifel; JMP Securities

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 16

FiledFormWhat it isName as filedEDGAR
2020-08-26S-1S-1 (registration)Athira Pharma, Inc.0001564590-20-041369 ↗
2020-09-09S-1/AS-1/A (amendment)Athira Pharma, Inc.0001564590-20-042848 ↗
2020-09-14S-1/AS-1/A (amendment)Athira Pharma, Inc.0001564590-20-043324 ↗
2020-09-17S-1/AS-1/A (amendment)Athira Pharma, Inc.0001564590-20-043758 ↗
2020-09-17S-1MEFS-1MEF (added securities)Athira Pharma, Inc.0001564590-20-043890 ↗
2020-09-17EFFECTEFFECT (declared effective)Athira Pharma, Inc.9999999995-20-002483 ↗
2020-09-18424B4424B4 (final prospectus)Athira Pharma, Inc.0001564590-20-043998 ↗
2021-01-19S-1S-1 (registration)Athira Pharma, Inc.0001564590-21-001397 ↗
2021-01-20EFFECTEFFECT (declared effective)Athira Pharma, Inc.9999999995-21-000203 ↗
2021-01-21424B4424B4 (final prospectus)Athira Pharma, Inc.0001564590-21-001770 ↗
2021-11-24EFFECTEFFECT (declared effective)Athira Pharma, Inc.9999999995-21-004485 ↗
2024-10-28EFFECTEFFECT (declared effective)Athira Pharma, Inc.9999999995-24-003298 ↗
2026-03-31S-1/AS-1/A (amendment)LeonaBio, Inc.0001193125-26-134866 ↗
2026-03-31S-1/AS-1/A (amendment)LeonaBio, Inc.0001193125-26-134904 ↗
2026-04-01EFFECTEFFECT (declared effective)LeonaBio, Inc.9999999995-26-001045 ↗
2026-04-01EFFECTEFFECT (declared effective)LeonaBio, Inc.9999999995-26-001046 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2020-09-17S-1/Aregistration statement$15.00–$17.0010,000,000-Nasdaq ATHA4primary document; range, shares headline, cover names 4document ↗
2020-09-18424B4final prospectus$17.0012,000,000$204,000,000Nasdaq ATHA4primary document; price sentence, shares headline, proceeds table, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
CHURCH KEVINOfficerChief Scientific Officer; CHIEF SCIENTIFIC OFFICER; Executive VP, Research; Vice President of Discovery232020–2026
EDELMAN JOSEPHDirector; Director,TenPercentOwner152020–2026
JOHNSON JAMES ADirector92020–2026
KAWAS LEENDirector,Officer; Director,Officer,TenPercentOwnerPresident & CEO22020–2021
Litton Mark JamesDirector,Officer; OfficerCEO; Chief Executive Officer; Chief Operating Officer; President and CEO; PRESIDENT and CEO202020–2026
MILESON GLENNAOfficerChief Financial Officer92020–2023
MOEBIUS HANSOfficerChief Medical Officer112020–2024
PERCEPTIVE ADVISORS LLCDirector; Director,TenPercentOwner; TenPercentOwner102020–2026
PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirector; Director,TenPercentOwner; TenPercentOwner102020–2026
RTW INVESTMENTS, LPTenPercentOwner22020
WONG RODERICKTenPercentOwner22020
Yamada TadatakaDirector22020–2021
FLUKE JOHN M JRDirector102020–2026person page Fuzzy
Romano Kelly ADirector122020–2026
Kosacz BarbaraDirector82021–2026
Worthington MarkOfficerGeneral Counsel; GENERAL COUNSEL; General Counsel and CCO; GENERAL COUNSEL and CCO172021–2026
Lenington RachelOfficerChief Operating Officer; Chief Technology Officer; COO and CDO; COO AND CDO92021–2024
PICKERING GRANTDirector102022–2026
Panzara Michael A.Director82022–2026
Gengos AndrewOfficerCFO and Chief Business Officer; CFO AND CHIEF BUSINESS OFFICER; See Below82023–2024
San Martin JavierOfficerCHIEF MEDICAL OFFICER102024–2026
Renninger RobertOfficerChief Financial Officer; CHIEF FINANCIAL OFFICER; SVP, Finance and Accounting; VP of Finance102024–2026
Perceptive Xontogeny Venture Fund II, LPDirector,TenPercentOwner12025
Callori FredDirector32026
Holles Natalie C.Director32026
Silverman Peter B.Director32026
Portman David J.TenPercentOwner12026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2020-06-12Athira Pharma, Inc.Biotechnology$90,944,020$89,007,350731
2018-12-20Athira Pharma, Inc.Biotechnology$4,650,000$3,816,000224
2015-11-20M3 Biotechnology, Inc.Biotechnology$17,000,000$14,115,000413
2014-10-03M3 Biotechnology, Inc.Other$1,200,000$350,00072

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationLeonaBio, Inc.WAState business registriesname and state
Plan sponsorLEONABIO, INC.WAForm 5500 (employee benefit plans)EIN (EXACT)
Form D issuerAthira Pharma, Inc.WAForm D private offeringsCIK (EXACT)
SEC filerLeonaBio, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerLEONABIO, INC.WATrademarks (USPTO)name and state
Form 5500 plan sponsorLEONABIO, INC.EIN (EXACT)
Person pageJohn M Fluke JrPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), WA first:

More with this interest.

In other datasets, the same topic (Health) in WA:

Interests: Biological Products, (No Diagnostic Substances) · Health